

2. Calogero AE, Gallucci WT, Gole PW, Chrousos GP. Multiple feedback regulatory loops upon rat hypothalamic corticotrophin-releasing hormone secretion. Potential clinical implications. *J Clin Invest.* 1998; **82**: 767–74.
3. Schule R, Rangarajan P, Kliewer S, Ransone LJ, Bolado J, Yang N, et al. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. *Cell.* 1990; **62**: 1217–26.
4. Ghosh S, Ma MJ, Kopp EB. NF- κ B and Rel proteins: evolutionarily conserved mediators of immune responses. *Annu Rev Immunol.* 1998; **16**: 225–60.
5. Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. *Annu Rev Immunol.* 2002; **20**: 125–63.
6. Baker C, Richards LJ, Dayan CM, Jessop DS. Corticotropin-releasing hormone immunoreactivity in human T and B cells and macrophages: co-localization with arginine vasopressin. *J Neuroendocrinol.* 2003; **15**: 1070–4.
7. Crofford LJ, Sano H, Karalis K, Webster EL, Goldmuntz EA, Chrousos GP, et al. Local secretion of corticotropin-releasing hormone in the joints of Lewis rats with inflammatory arthritis. *J Clin Invest.* 1992; **90**: 2555–64.
8. Kempuraj D, Papadopoulou NG, Lytinas M, Huang M, Kandere-Grzybowska K, Madhappan B, et al. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. *Endocrinology.* 2004; **145**: 43–8.
9. Zheng PY, Feng BS, Oluwole C, Struiksma S, Chen X, Li P, et al. Psychological stress induces eosinophils to produce corticotropin releasing hormone in the intestine. *Gut.* 2009; **58**: 1473–9.
10. Agelaki S, Tsatsanis C, Gravanis A, Margioris AN. Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice. *Infect Immun.* 2002; **70**: 6068–74.
11. Tanriverdi F, Silveira LF, MacColl GS, Bouloux PM. The hypothalamic-pituitary-gonadal axis: immune function and autoimmunity. *J Endocrinol.* 2003; **176**: 293–304.
12. Chen A, Ganor Y, Rahimipour S, Ben-Aroya N, Koch Y, Levite M. The neuropeptides GnRH-II and GnRH-I are produced by human T cells and trigger laminin receptor gene expression, adhesion, chemotaxis and homing to specific organs. *Nat Med.* 2002; **8**: 1421–6.
13. Jacobson JD, Ansari MA, Kinealy M, Muthukrishnan V. Gender-specific exacerbation of murine lupus by gonadotropin-releasing hormone: potential role of G alpha q/11. *Endocrinology.* 1999; **140**: 3429–37.
14. Cheskis BJ, Greger JG, Ngpal S, Freedman LP. Signaling by estrogens. *J Cell Physiol.* 2007; **213**: 610–7.
15. Wilder RL, Elenkov IJ. Hormonal regulation of tumor necrosis factor- α , interleukin-12 and interleukin-10 production by activated macrophages. *Ann NY Acad Sci.* 1999; **876**: 14–31.
16. Chrousos PG, Torpy DJ, Gold PW. Interactions between the hypothalamic-pituitary-adrenal axis and the female reproductive system: clinical implications. *Ann Intern Med.* 1998; **129**: 229–40.
17. Bynoe MS, Grimaldi CM, Diamond B. Estrogen up-regulates Bcl-2 and blocks tolerance induction of naïve B cells. *Proc Natl Acad Sci USA.* 2000; **97**: 2703–8.
18. Grimaldi CM, Michael DJ, Diamond B. Expansion and activation of a population of autoreactive marginal zone B cells in a model of estrogen-induced lupus. *J Immunol.* 2001; **167**: 1886–90.
19. Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. *J Clin Invest.* 2002; **109**: 1625–33.
20. Jansson L, Olsson T, Holmdahl R. Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice. *J Neuroimmunol.* 1994; **53**: 203–7.
21. Kim S, Liva SM, Dalal MA, Verity MA, Voskuhl RR. Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. *Neurology.* 1999; **52**: 1230–8.
22. Bebo BF Jr, Fyfe-Johnson A, Adlard K, Beam AG, Vandenberg AA, Offner H. Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. *J Immunol.* 2001; **166**: 2080–9.
23. Lin HB, Loo KK, Palasynski K, Ashouri J, Lubahn DB, Voskuhl RR. Estrogen receptor alpha mediates estrogen's immune protection in autoimmune disease. *J Immunol.* 2003; **171**: 6936–40.
24. Palasynski KM, Liu H, Loo KK, Voskuhl RR. Estriol treatment ameliorates disease in males with experimental autoimmune encephalomyelitis: implications for multiple sclerosis. *J Neuroimmunol.* 2004; **149**: 84–9.
25. Wang C, Dehghani B, Li Y, Laurie J, Kaler J, Arthur A, et al. Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death-1. *Immunology.* 2009; **126**: 329–35.
26. Polanczyk M, Zamora A, Subramanian S, Matejuk A, Hess DL, Blankenhorn EP, et al. The protective effect of 17 β -estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor- α . *Am J Pathol.* 2003; **163**: 1599–605.
27. Elloso MM, Phiel K, Henderson RA, Harris HA, Adelman SJ. Suppression of experimental autoimmune encephalomyelitis using estrogen receptor-selective ligands. *J Endocrinol.* 2005; **185**: 243–52.
28. Morales LB, Loo KK, Liu H-b, Peterson C, Tiwari-Woodruff S, Voskuhl RR. Treatment with an estrogen receptor α ligand is neuroprotective in experimental

- autoimmune encephalomyelitis. *J Neurosci.* 2006; **26**: 6823–33.
29. Tiwari-Woodruff S, Morales LB, Lee R, Voskuhl RR. Differential neuroprotective and anti-inflammatory effects of estrogen receptor (ER)α and ERβ ligand treatment. *Proc Natl Acad Sci USA.* 2007; **104**: 14813–8.
 30. Crawford DK, Mangiardi M, Song B, Patel R, Du S, Sofroniew MV, et al. Oestrogen receptor β ligand: a novel treatment to enhance endogenous functional remyelination. *Brain.* 2010; **133**: 2999–3016.
 31. Wang C, Dehghani B, Li Y, Kaler LJ, Proctor T, Vandembark AA. Membrane estrogen receptor regulates EAE through upregulation of programmed death 1. *J Immunol.* 2009; **182**: 3294–303.
 32. Blasko E, Haskell CA, Leung S, Gualtieri G, Halks-Miller M, Mahmoudi M, et al. Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. *J Neuroimmunol.* 2009; **214**: 67–77.
 33. Yates MA, Li Y, Chlebeck PJ, Offner H. GPR30, but not estrogen receptor-α, is crucial in the treatment of experimental autoimmune encephalomyelitis by oral ethinyl estradiol. *BMC Immunol.* 2010; **11**: 20.
 34. Gold SM, Voskuhl RR. Estrogen treatment in multiple sclerosis. *J Neurol Sci.* 2009; **86**: 99–103.
 35. Sicotte NL, Liva SM, Klutch R, Pfeiffer P, Bouvier S, Odesa S, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. *Ann Neurol.* 2002; **52**: 421–8.
 36. Vukusic S, Ionescu I, El-Etr M, Schumacher M, Baulieu EE, Cornu C, et al. The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPARTMUS) trial: rationale, objectives and state of advancement. *J Neurol Sci.* 2009; **286**: 114–8.
 37. Kalkhoven E, Wissink S, van der Saag PT, van der Burg B. Negative interaction between the RelA(p65) subunit of the NF-κappaB and the progesterone receptor. *J Biol Chem.* 1996; **271**: 6217–24.
 38. Araneo BA, Dowell T, Diegel M, Daynes RA. Dihydrotestosterone exerts a depressive influence on the production of interleukin-4 (IL-4), IL-5, and gamma-interferon, but not IL-2 by activated murine T cells. *Blood.* 1991; **78**: 688–99.
 39. Gerlo S, Verdood P, Hooghe-Peters EL, Kooijman R. Modulation of prolactin expression in human T lymphocytes by cytokines. *J Neuroimmunol.* 2005; **162**: 190–3.
 40. Matalka KZ. Prolactin enhances production of interferon-γ, interleukin-12, and interleukin-10, but not of tumor necrosis factor-α, in a stimulus-specific manner. *Cytokine.* 2003; **21**: 187–94.
 41. Peeva E, Michael D, Cleary J, Rice J, Chen X, Diamond B. Prolactin modulates the naïve B cell repertoire. *J Clin Invest.* 2003; **111**: 275–83.
 42. Peeva E, Grimaldi C, Spatz L, Diamond B. Bromocriptine restores tolerance in estrogen-treated mice. *J Clin Invest.* 2000; **106**: 1373–9.
 43. Saha S, Gonzalez J, Rosenfeld G, Keiser H, Peeva E. Prolactin alters the mechanisms of B cell tolerance induction. *Arthritis Rheum.* 2009; **60**: 1743–52.
 44. Arpin C, Pihlgren M, Fraichard A, Aubert D, Samarut J, Chassande O, et al. Effects of T3Ra1 and T3Ra2 gene deletion on T and B lymphocyte development. *J Immunol.* 2000; **164**: 152–60.
 45. Schoenfeld PS, Myers JW, Myers L, LaRocque JC. Suppression of cell-mediated immunity in hypothyroidism. *South Med J.* 1995; **88**: 347–9.
 46. Klecha AJ, Genaro AM, Lysionek AE, Caro LA, Coluccia AG, Cremaschi GA. Experimental evidence pointing to the bidirectional interaction between the immune system and the thyroid axis. *Int J Immunopharmacol.* 2000; **22**: 491–500.
 47. Klecha AJ, Genaro AM, Gorelik G, Arcos MLB, Silberman DM, Schuman M, et al. Integrative study of hypothalamus-pituitary-thyroid-immune system interaction: thyroid hormone-mediated modulation of lymphocyte activity through the protein kinase C signaling pathway. *J Endocrinol.* 2006; **189**: 45–55.
 48. Frick LR, Rapanelli M, Bussmann UA, Klecha AJ, Arcos ML, Genaro AM, et al. Involvement of thyroid hormones in the alterations of T-cell immunity and tumor progression induced by chronic stress. *Biol Psychiatry.* 2009; **65**: 935–42.
 49. Kitazono T, Padgett RC, Armstrong M, Tompkins PK, Heistad DD. Evidence that angiotensin II is present in human monocytes. *Circulation.* 1995; **91**: 1129–34.
 50. Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Takiuchi S, Moriguchi K, et al. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. *J Hypertens.* 1999; **17**: 537–45.
 51. Nahmod KA, Vermeulen ME, Raiden S, Salamone G, Gamberale R, Fernández-Calotti P, et al. Control of dendritic cell differentiation by angiotensin II. *FASEB J.* 2003; **17**: 491–3.
 52. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, Lorenzo O, Plaza JJ, Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-κappa B activation and monocyte chemoattractant protein-1 synthesis. *J Immunol.* 1998; **161**: 430–9.
 53. Kranzhofer R, Browatzki M, Schmidt J, Kubler W. Angiotensin II activates the proinflammatory transcription factor nuclear factor-κappa B in human monocytes. *Biochem Biophys Res Commun.* 1999; **257**: 826–8.
 54. Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. *Circulation.* 1998; **98**: 800–7.
 55. Nabah YNA, Mateo T, Estellés R, Mata M, Zagorski J, Sarau H, et al. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. *Circulation.* 2004; **110**: 3581–6.

56. Fukuzawa M, Satoh J, Sagara M, Muto G, Muto Y, Nishimura S, et al. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor- α in vitro and in vivo. *Immunopharmacology*. 1997; **36**: 49–55.
57. Lapteva N, Ide K, Nieda M, Ando Y, Hatta-Ohashi Y, Minami M, et al. Activation and suppression of rennin-angiotensin system in human dendritic cells. *Biochem Biophys Res Commun*. 2002; **296**: 194–200.
58. Sánchez-Lemus E, Benicky J, Pavel J, Saavedra JM. In vivo angiotensin II AT1 receptor blockade selectively inhibits LPS-induced innate immune response and ACTH release in rat pituitary gland. *Brain Behav Immun*. 2009; **23**: 945–57.
59. Dalbeth N, Edwards J, Fairchild S, Callan M, Hall FC. The non-thiol-angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis. *Rheumatology*. 2005; **44**: 24–31.
60. Sagawa K, Nagatani K, Komagata Y, Yamamoto K. Angiotensin receptor blockers suppress antigen-specific T cell responses and ameliorate collagen-induced arthritis in mice. *Arthritis Rheum*. 2005; **52**: 1920–8.
61. Okunuki Y, Usui Y, Nagai N, Kezuka T, Ishida S, Takeuchi M, et al. Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan. *Invest Ophthalmol Vis Sci*. 2009; **50**: 2255–61.
62. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. *Proc Natl Acad Sci USA*. 2009; **106**: 14948–53.
63. Lanz TV, Ding Z, Ho PP, Luo J, Agrawal AN, Srinagesh H, et al. Angiotensin II sustains brain inflammation in mice via TGF- β . *J Clin Invest*. 2010; **120**: 2782–94.
64. Guzik TJ, Mangalat D, Korbut R. Adipocytokines – novel link between inflammation and vascular function? *J Physiol Pharmacol*. 2006; **57**: 505–28.
65. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. *Nat Rev Immunol*. 2006; **6**: 772–83.
66. Wong CK, Cheung PF, Lam CW. Leptin-mediated cytokine release and migration of eosinophils: implications for immunopathophysiology of allergic inflammation. *Eur J Immunol*. 2007; **37**: 2337–48.
67. Caldefie-Chezet F, Poulin A, Vasson MP. Leptin regulates functional capacities of polymorphonuclear neutrophils. *Free Radic Res*. 2003; **37**: 809–14.
68. Montecucco F, Bianchi G, Gnerre P, Bertolotto M, Dall'egri F, Ottonello L. Induction of neutrophil chemotaxis by leptin: crucial role for p38 and Src kinases. *Ann NY Acad Sci*. 2006; **1069**: 463–71.
69. Lord GM, Matarese G, Howard JK, Baker RJ, Bloon SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. *Nature*. 1998; **394**: 897–901.
70. Sanna V, Di Giacomo A, La Cava A, Lechler RI, Fontana S, Zappacosta S, et al. Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. *J Clin Invest*. 2003; **111**: 241–50.
71. Okamoto Y, Folco EJ, Minami M, Wara AK, Feinberg MW, Sukhova GK, et al. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherosclerosis. *Circ Res*. 2008; **102**: 218–25.
72. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. *Blood*. 2000; **96**: 1723–32.
73. Shwarz H, Villiger PM, von Kempis J, Lotz M. Neuropeptide Y is an inducible gene in the human immune system. *J Neuroimmunol*. 1994; **51**: 53–61.
74. Straub RH, Schaller T, Miller LE, von Hörsten S, Jessop DS, Falk W, et al. Neuropeptide Y cotransmission with norepinephrine in the sympathetic nerve-macrophage interplay. *J Neurochem*. 2000; **7**: 2464–71.
75. Bedoui S, Miyake S, Lin Y, Miyamoto K, Oki S, Kawamura N, et al. Neuropeptide Y (NPY) suppresses experimental autoimmune encephalomyelitis: NPY1 receptor-specific inhibition of autoreactive Th1 responses in vivo. *J Immunol*. 2003; **171**: 3451–8.
76. Wheway J, Mackay CR, Newton RA, Sainsbury A, Boey D, Herzog H, et al. A fundamental bimodal role for neuropeptide Y1 receptor in the immune system. *J Exp Med*. 2005; **202**: 1527–38.
77. Cowley MA, Smith RG, Diano S, Tschöp M, Pronchuk N, Grove KL, et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. *Neuron*. 2003; **37**: 649–61.
78. Kalra SP, Ueno N, Kalra PS. Stimulation of appetite by ghrelin is regulated by leptin restraint: peripheral and central sites of action. *J Nutr*. 2005; **135**: 1331–5.
79. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, et al. A role for ghrelin in the central regulation of feeding. *Nature*. 2001; **409**: 194–8.
80. Wu JTR, Dral J. Ghrelin integrative neuroendocrine peptide in health and disease. *Ann Surg*. 2004; **239**: 464–74.
81. Koo GC, Huang C, Camacho R, Trainor C, Blake JT, Sirotna-Meisher A, et al. Immune enhancing effect of a growth hormone secretagogue. *J Immunol*. 2001; **16**: 4195–201.
82. Li WG, Gavrilu D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, et al. Ghrelin inhibits proinflammatory responses and nuclear factor- κ B activation in human endothelial cells. *Circulation*. 2004; **109**: 2221–6.
83. Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R, et al. Ghrelin inhibits leptin- and

- activation-induced proinflammatory cytokine expression by human monocytes and T cells. *J Clin Invest.* 2004; **114**: 57–66.
84. Gonzalez-Rey E, Chorny A, Delgado M. Therapeutic action of ghrelin in a mouse model of colitis. *Gastroenterology.* 2006; **130**: 1707–20.
 85. Granado M, Priego T, Martin AI, Villanua A, Lopez-Caldron A. Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. *Am J Physiol Endocrinol Metab.* 2005; **288**: E486–92.
 86. Chorny A, Anderson P, Gonzalez-Rey E, Delgado M. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. *J Immunol.* 2008; **180**: 8369–77.
 87. Wu R, Dong W, Cui X, Zhou M, Simms HH, Ravikumar TS, et al. Ghrelin down-regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. *Ann Surg.* 2007; **245**: 480–6.
 88. Theil M-M, Miyake S, Mizuno M, Tomi C, Croxford JL, Hosoda H, et al. Suppression of experimental autoimmune encephalomyelitis by ghrelin. *J Immunol.* 2009; **183**: 2859–66.
 89. Miyake S, Yamamura T. Ghrelin: friend or foe for neuroinflammation. *Discov Med.* 2009; **8**: 64–7.
 90. Sloan EK, Capitanio JP, Tarara RP, Mendoza SP, Mason WA, Cole SW. Social stress enhances sympathetic innervation of primate lymph nodes: mechanisms and implications for viral pathogenesis. *J Neurosci.* 2007; **27**: 8857–65.
 91. Sloan EK, Capitanio JP, Cole SW. Stress-induced remodeling of lymphoid innervation. *Brain Behav Immun.* 2008; **22**: 15–21.
 92. Straub RH, Rauch L, Fassold A, Lowin T, Pongratz G. Neuronally released sympathetic neurotransmitters stimulate splenic interferon-gamma secretion from T cells in early type II collagen-induced arthritis. *Arthritis Rheum.* 2008; **58**: 3450–60.
 93. Sloan EK, Nguyen CT, Cox BF, Tarara RP, Capitanio JP, Cole SW. SIV infection decreases sympathetic innervation of primate lymph nodes: the role of neurotrophins. *Brain Behav Immun.* 2008; **22**: 185–94.
 94. Elenkov IJ, Papanicolaou DA, Wilder RL, Chrousos GP. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. *Proc Assoc Am Physicians.* 1996; **108**: 374–81.
 95. Le Tulzo Y, Shenkar R, Kaneko D, Moine P, Fantuzzi G, Dinarello CA, et al. Hemorrhage increases cytokine expression in lung mononuclear cells in mice: involvement of catecholamines in nuclear factor-kappaB regulation and cytokine expression. *J Clin Invest.* 1997; **99**: 1516–24.
 96. Panina-Bordignon P, Mazzeo D, Lucia PD, D'Ambrosio D, Lang R, Fabbri L, et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. *J Clin Invest.* 1997; **100**: 1513–9.
 97. Kin NW, Sanders VM. It takes nerve to tell T and B cells what to do. *J Leukoc Biol.* 2006; **79**: 1093–104.
 98. Strell C, Sievers A, Bastian P, Lang K, Niggemann B, Zänker KS, et al. Divergent effects of norepinephrine, dopamine and substance P on the activation, differentiation and effector functions of human cytotoxic T lymphocytes. *BMC Immunol.* 2009; **8**: 10.
 99. Bhowmick S, Singh A, Flavell RA, Clark RB, O'Rourke J, Cone RE. The sympathetic nervous system modulates CD4(+)FoxP3(+) regulatory T cells via a TGF-beta-dependent mechanism. *J Leukoc Biol.* 2009; **86**: 1275–83.
 100. Grebe KM, Hickman HD, Irvine KR, Takeda K, Bennink JR, Yewdell JW. Sympathetic nervous system control of anti-influenza CD8+ T cell responses. *Proc Natl Acad Sci USA.* 2009; **106**: 5300–5.
 101. Kohm AP, Sanders VM. Norepinephrine and beta 2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. *Pharm Rev.* 2001; **53**: 487–525.
 102. Lucin KM, Sanders VM, Jones TB, Malarkey WB, Popovich PG. Impaired antibody synthesis after spinal cord injury is level dependent and is due to sympathetic nervous system dysregulation. *Exp Neurol.* 2007; **207**: 75–84.
 103. Harvath L, Robbins JD, Russell AA, Seamon KB. cAMP and human neutrophil chemotaxis. Elevation of cAMP differentially affects chemotactic responsiveness. *J Immunol.* 1991; **146**: 224–32.
 104. Barnett CC, Moore EE, Partrick DA, Silliman CC. Beta-adrenergic stimulation down-regulates neutrophil priming for superoxide generation, but not elastase release. *J Surg Res.* 1997; **70**: 166–70.
 105. Layé S, Bluthé RM, Kent S, Combe C, Médina C, Parnet P, et al. Subdiaphragmatic vagotomy blocks induction of IL-1 beta mRNA in mice brain in response to peripheral LPS. *Am J Physiol.* 1995; **268**: R1327–31.
 106. van Maanen MA, Lebre MC, van der Poll T, LaRosa GJ, Elbaum D, Vervoordeldonk MJ, et al. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. *Arthritis Rheum.* 2009; **60**: 114–22.
 107. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. *Nature.* 2000; **405**: 458–62.
 108. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susara S, et al. Nicotinic acetylcholine receptor $\alpha 7$ subunit is an essential regulator of inflammation. *Nature.* 2003; **421**: 384–8.
 109. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. *Nat Med.* 2004; **10**: 1216–21.

110. Shi FD, Piao WH, Kuo YP, Campagnolo DI, Vollmer TL, Lukas RJ. Nicotinic attenuation of central nervous system inflammation and autoimmunity. *J Immunol.* 2009; **182**: 1730–9.
111. Nizri E, Irony-Tur-Sinai M, Lory O, Orr-Urtreger A, Lavi E, Brenner T. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. *J Immunol.* 2009; **183**: 6681–8.
112. Fujii YX, Fujigaya H, Moriwaki Y, Misawa H, Kasahara T, Grando SA, et al. Enhanced serum antigen-specific IgG₁ and proinflammatory cytokine production in nicotinic acetylcholine receptor $\alpha 7$ subunit gene knockout mice. *J Neuroimmunol.* 2007; **189**: 69–74.
113. van der Zanden EP, Snoek SA, Heinsbroek SE, Stanisor OI, Verseijden C, Boeckxstaens GE, et al. Vagus nerve activity augments intestinal macrophage phagocytosis via nicotinic acetylcholine receptor $\alpha 4\beta 2$. *Gastroenterology.* 2009; **189**: 1029–39.
114. Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, et al. MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. *Immunity.* 2009; **131**: 965–73.
115. Levite M. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. *Curr Opin Pharmacol.* 2008; **8**: 460–71.
116. Nakano K, Higashi T, Takagi R, Hashimoto K, Tanaka Y, Matsushita S. Dopamine released by dendritic cells polarizes Th2 differentiation. *Int Immunol.* 2009; **21**: 645–54.
117. Bergquist J, Tarkowski A, Ekman R, Ewing A. Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. *Proc Natl Acad Sci USA.* 1994; **91**: 12912–6.
118. Flierl MA, Rittirsch D, Nadeau BA, Chen AJ, Sarma V, Zetovone F, et al. Phagocyte-derived catecholamines enhance acute inflammatory injury. *Nature.* 2007; **449**: 721–6.
119. Cosentino M, Fietta AM, Ferrari M, Rasini E, Bombelli R, Carcano E, et al. Human CD4⁺CD25⁺ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. *Blood.* 2007; **109**: 632–42.
120. Agulia MC, Dees WL, Haensly WE, McCann M. Evidence that somatostatin is localized and synthesized in lymphoid organs. *Proc Natl Acad Sci USA.* 1991; **88**: 11485–9.
121. De Giorgio R, Tazzari PL, Barbara G, Stanhellini V, Corinaldesi R. Detection of substance P immunoreactivity in human peripheral leukocytes. *J Neuroimmunol.* 1998; **82**: 175–81.
122. Li Y, Tian S, Douglas SD, Ho WZ. Morphine up-regulates expression of substance P and its receptor in human blood mononuclear phagocytes and lymphocytes. *Cell Immunol.* 2000; **205**: 120–7.
123. Qian BF, Zhou GQ, Hammarstrom ML, Danielsson A. Both substance P and its receptor are expressed in mouse intestinal T lymphocytes. *Neuroendocrinology.* 2001; **73**: 358–68.
124. Arsenescu R, Blum AM, Metwali A, Elliott DE, Weinstock JV. IL-12 induction of mRNA encoding substance P in murine macrophages from the spleen and sites of inflammation. *J Immunol.* 2005; **174**: 3906–11.
125. Mousa SA, Straub R, Schafer M, Stein C. Beta-endorphin, Met-enkephalin and corresponding opioid receptors within synovium of patients with joint trauma, osteoarthritis and rheumatoid arthritis. *Ann Rheum Dis.* 2007; **66**: 871–9.
126. Bracci-Laudiero L, Aloe L, Buanne P, Finn A, Stenfors C, Vigneti E, et al. NGF modulates CGRP synthesis in human B-lymphocytes: a possible anti-inflammatory action on NGF? *J Neuroimmunol.* 2002; **123**: 58–65.
127. Bracci-Laudiero L, Aloe L, Caroleo MC, Buanne P, Costa N, Starace G, et al. Endogenous NGF regulates CGRP expression in human monocytes, and affects HLA-DR and CD86 expression and IL-10 production. *Blood.* 2005; **106**: 3507–14.
128. Xing L, Guo J, Wang X. Induction and expression of β -calcitonin gene-related peptide in rat T lymphocytes and its significance. *J Immunol.* 2000; **165**: 4359–66.
129. Gomariz RP, Leceta J, Garrido E, Garrido T, Delgado M. Vasoactive intestinal peptide (VIP) mRNA expression in rat T and B lymphocytes. *Regul Pept.* 1994; **50**: 177–84.
130. Martinez C, Delgado M, Abad C, Gomariz RP, Ganea D, Leceta J. Regulation of VIP production and secretion by murine lymphocytes. *J Neuroimmunol.* 1999; **93**: 126–38.
131. Ganor Y, Besser M, Ben-Zakay N, Unger T, Levite M. Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration. *J Immunol.* 2003; **170**: 4362–72.
132. Pitt D, Werner P, Paine CS. Glutamate excitotoxicity in a model of multiple sclerosis. *Nat Med.* 2000; **6**: 67–70.
133. Pacheco R, Oliva H, Martinez-Navio JM, Climent N, Ciruela F, Gatell JM, et al. Glutamate released by dendritic cells as a novel modulator of T cell activation. *J Immunol.* 2006; **177**: 6695–704.
134. Pacheco R, Ciruela F, Casado V, Mallol J, Gallart T, Lluis C, et al. Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation. *J Biol Chem.* 2004; **279**: 33352–8.
135. Fallarino F, Volpi C, Fazio F, Notartomaso S, Vacca C, Busceti C, et al. Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. *Nat Med.* 2010; **16**: 897–902.
136. Bergquist J, Josefsson E, Tarkowski A, Ekman R, Ewing A. Measurements of catecholamine-mediated apoptosis of immunocompetent cells by capillary electrophoresis. *Electrophoresis.* 1997; **18**: 1760–6.

137. Ghosh MC, Mondal AC, Basu S, Banerjee S, Majumdar J, Bhattacharya D, et al. Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells. *Int Immunopharmacol.* 2003; **3**: 1019–26.
138. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. *Physiol Rev.* 1998; **78**: 189–225.
139. Saha B, Mondal AC, Majumder J, Basu S, Dasgupta PS. Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4+ and CD8+ T cells in vitro: a receptor-mediated mechanism. *Neuroimmunomodulation.* 2001; **9**: 23–33.
140. Kipnis J, Cardon M, Avidan H, Lewitus GM, Mordechai S, Rolls A, et al. Dopamine, through the extracellular signal regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration. *J Neurosci.* 2004; **4**: 6133–43.
141. Levite M, Chowers Y, Ganor Y, Besser M, HersHKovits R, Cahalon L. Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta1 integrin function. *Eur J Immunol.* 2001; **31**: 3504–12.
142. Besser MJ, Ganor Y, Levite M. Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both. *J Neuroimmunol.* 2005; **169**: 161–71.
143. Watanabe Y, Nakayama T, Nagakubo D, Hieshima K, Jin Z, Katou F, et al. Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3. *J Immunol.* 2006; **176**: 848–56.
144. Nakano K, Higashi T, Hashimoto K, Takagi Ri, Tanaka Y, Matsushita S. Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. *Biochem Biophys Res Commun.* 2008; **373**: 286–91.
145. Nakano K, Yamaoka K, Hanami K, Saito K, Sasaguri Y, Yanagihara N, et al. Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 Naïve T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model. *J Immunol.* 2011; **186**: 3745–52.
146. Lotz M, Vaughan JH, Carson DA. Effects of neuropeptides on production of inflammatory cytokines by human monocytes. *Science.* 1988; **241**: 1218–21.
147. Calvo CF, Chavanel G, Senik A. Substance P enhances IL-2 expression in activated human T cells. *J Immunol.* 1992; **148**: 3498–504.
148. Mathers AR, Tckacheva OA, Janelsins BM, Shufesky WJ, Morelli AE, Larregina AT. In vivo signaling through the neurokinin 1 receptor favors transgene expression by Langerhans cells and promotes the generation of Th1- and Tc1-biased immune responses. *J Immunol.* 2007; **178**: 7006–17.
149. Cunin P, Caillon A, Corvaisier M, Garo E, Scotet M, Blanchard S, et al. The tachykinins substance P and hemokinin-1 favor the generation of human memory Th17 cells by inducing IL-1 β , IL-23, and TNF-like 1A expression by monocytes. *J Immunol.* 2011; **186**: 4175–82.
150. Hegde A, Zhang H, Mochhala SM, Bhatia M. Neurokinin-1 receptor antagonist treatment protects mice against lung injury in polymicrobial sepsis. *J Leukoc Biol.* 2007; **82**: 678–85.
151. Gad M, Pedersen AE, Kristensen NN, Fernandez Cde F, Claesson MH. Blockage of the neurokinin 1 receptor and capsaicin-induced ablation of the enteric afferent nerves protect SCID mice against T-cell-induced chronic colitis. *Inflamm Bowel Dis.* 2009; **15**: 1174–82.
152. Hegde A, Koh YH, Mochhala SM, Bhatia M. Neurokinin-1 receptor antagonist treatment in polymicrobial sepsis: molecular insights. *Int J Inflamm.* 2010; **2010**: 601098.
153. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci.* 2008; **9**: 46–57.
154. Rettori V, Gimeno MF, Karara A, Gonzalez MC, McCann SM. Interleukin 1 alpha inhibits prostaglandin E2 release to suppress pulsatile release of luteinizing hormone but not follicle-stimulating hormone. *Proc Natl Acad Sci USA.* 1991; **88**: 2763–7.
155. Bluthé RM, Kelley KW, Dantzer R. Effects of insulin-like growth factor-I on cytokine-induced sickness behavior in mice. *Brain Behav Immun.* 2006; **20**: 57–63.
156. Dantzer R, Gheusi G, Johnson RW, Kelley KW. Central administration of insulin-like growth factor-1 inhibits lipopolysaccharide-induced sickness behavior in mice. *Neuroreport.* 1999; **10**: 289–92.
157. Dantzer R, Gheusi G, Johnson RW, Kelley KW. Central injection of IL-10 antagonizes the behavioural effects of lipopolysaccharide in rats. *Psychoneuroendocrinology.* 1999; **24**: 301–11.
158. Leon LR, Kozak W, Rudolph K, Kluger MJ. An antipyretic role for interleukin-10 in LPS fever in mice. *Am J Physiol.* 1999; **276**: R81–9.
159. Perkins MN, Stone TW. An iontophoretic investigation of actions of convulsant kynurenes and their interaction with endogenous excitant quinolinic acid. *Brain Res.* 1982; **247**: 184–7.
160. Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? *J Exp Med.* 1999; **189**: 865–70.
161. Kipnis J, Cohen H, Cardon M, Ziv Y, Schwartz M. T cell deficiency leads to cognitive dysfunction: implications

- for therapeutic vaccination for schizophrenia and other psychiatric conditions. *Proc Natl Acad Sci USA*. 2004; **101**: 8180–5.
162. Ziv Y, Ron N, Butovsky O, Landa G, Sudai E, Greenberg N, et al. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. *Nat Neurosci*. 2006; **9**: 268–75.
163. Wolf SA, Steiner B, Akpınarlı A, Kammertoens T, Nasenstein C, Braun A, et al. CD4-positive T lymphocytes provide a neuroimmunological link in the control of adult hippocampal neurogenesis. *J Immunol*. 2009; **182**: 3979–84.
164. Abbas N, Bednar I, Mix E, Marie S, Paterson DL, Jungberg A, et al. Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. *J Neuroimmunol*. 2002; **126**: 50–7.
165. Straub RH, Dhabhar FS, Bijlsma WJ, Cutolo M. How psychological stress via hormones and nerve fibers may exacerbate rheumatoid arthritis. *Arthritis Rheum*. 2005; **52**: 16–26.
166. Jara LJ, Navarro C, Medina G, Vera-Lastra O, Blanco F. Immune-neuroendocrine interactions and autoimmune diseases. *Clin Dev Immunol*. 2006; **13**: 109–23.

Mucosal-Associated Invariant T Cells Promote Inflammation and Exacerbate Disease in Murine Models of Arthritis

Asako Chiba, Ryohsuke Tajima, Chiharu Tomi, Yusei Miyazaki, Takashi Yamamura, and Sachiko Miyake

Objective. The function of mucosal-associated invariant T (MAIT) cells remains largely unknown. We previously reported an immunoregulatory role of MAIT cells in an animal model of multiple sclerosis. The aim of this study was to use animal models to determine whether MAIT cells are involved in the pathogenesis of arthritis.

Methods. MR1^{-/-} and MR1^{+/+} DBA/1J mice were immunized with bovine type II collagen (CII) in complete Freund's adjuvant to trigger collagen-induced arthritis (CIA). To assess CII-specific T cell recall responses, lymph node cells from mice with CIA were challenged with CII *ex vivo*, and cytokine production and proliferation were evaluated. Serum levels of CII-specific antibodies were measured by enzyme-linked immunosorbent assay. Collagen antibody-induced arthritis (CAIA) was induced in MR1^{-/-} and MR1^{+/+} C57BL/6 mice by injection of anti-CII antibodies followed by injection of lipopolysaccharide. To demonstrate the involvement of MAIT cells in arthritis, we induced CAIA in MR1^{-/-} C57BL/6 mice that had been reconstituted with adoptively transferred MAIT cells. MAIT cell activation in response to cytokine stimulation was investigated.

Results. The severity of CIA was reduced in MR1^{-/-} DBA/1J mice. However, T and B cell responses

to CII were comparable in MR1^{-/-} and MR1^{+/+} DBA/1J mice. MR1^{-/-} C57BL/6 mice were less susceptible to CAIA, and reconstitution with MAIT cells induced severe arthritis in MR1^{-/-} C57BL/6 mice, demonstrating an effector role of MAIT cells in arthritis. MAIT cells became activated upon stimulation with interleukin-23 (IL-23) or IL-1 β in the absence of T cell receptor stimuli.

Conclusion. These results indicate that MAIT cells exacerbate arthritis by enhancing the inflammation.

Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation in the joints. It has been suggested that environmental factors influence autoimmunity, and in particular, increasing evidence highlights the important role of gut flora in the development of autoimmune diseases (1), including arthritis. For example, differences in the intestinal microbiota of patients with early RA have been described, and tetracycline treatment was shown to reduce disease activity in RA (2,3). In addition, oral vancomycin treatment significantly decreased the severity of adjuvant-induced arthritis (4). More recently, it was demonstrated that germ-free conditions strongly inhibit arthritis in the K/BxN arthritis model and that the introduction of segmented filamentous bacteria induced severe arthritis in germ-free K/BxN mice (5). Thus, mucosal immunity plays an important role in the development and progression of arthritis.

Natural killer (NK) cells, invariant NK T (iNKT) cells, γ/δ T cells, mucosal-associated invariant T (MAIT) cells, B-1 B cells, and marginal-zone B cells are categorized as innate-like lymphocytes. Such lymphocytes reside in unique locations, including the marginal zone of the spleen and epithelial and mucosal tissues and rapidly exert effector functions in the absence of clonal expansion (6–15). Therefore, these innate-like lymphocytes are thought to play important roles in “first-line” im-

Supported by the Japan Foundation for Neuroscience and Mental Health (to Dr. Chiba), the Japan Rheumatism Foundation (to Dr. Chiba), the Japan Society for the Promotion of Science (Grants-in-Aid for Scientific Research B: 20390284 and 23390261 to Dr. Miyake), and the Ministry of Health, Labor, and Welfare of Japan (Health and Labor Sciences Research Grants on Intractable Diseases).

Asako Chiba, MD, PhD, Ryohsuke Tajima, MS, Chiharu Tomi, Yusei Miyazaki MD, PhD, Takashi Yamamura MD, PhD, Sachiko Miyake MD, PhD: National Institute of Neuroscience, National Centre of Neurology and Psychiatry, Tokyo, Japan.

Address correspondence to Sachiko Miyake MD, PhD, Department of Immunology, National Institute of Neuroscience, National Centre of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8502, Japan. E-mail: miyake@ncnp.go.jp.

Submitted for publication May 15, 2011; accepted in revised form August 25, 2011.

mune responses against exogenous stimuli. As MAIT cells are preferentially located in the gut lamina propria, there is a growing interest in the function of MAIT cells in various types of immune responses, including autoimmunity (16–20).

MAIT cells are restricted by a nonpolymorphic class IB major histocompatibility complex (MHC) molecule, the class I MHC-related molecule (MR1), and express an invariant T cell receptor (TCR) α -chain: $V_{\alpha}7.2$ - $J_{\alpha}33$ in humans and $V_{\alpha}19$ - $J_{\alpha}33$ in mice. The invariant TCR α chain associates with a limited set of V_{β} chains (14,21,22). MAIT cells are selected in the thymus in an MR1-dependent manner, but, interestingly, MAIT cells require B cells as well as commensal flora for their peripheral expansion (14,23). Our group previously demonstrated a protective role of MAIT cells against autoimmune encephalomyelitis (EAE), an animal model of human multiple sclerosis. The suppression of EAE was accompanied by increased production of interleukin-10 (IL-10) by B cells, which was induced in part by ICOS costimulation (17). Because the invariant $V_{\alpha}7.2$ - $J_{\alpha}33$ TCR is highly expressed in central nervous system lesions of multiple sclerosis patients, human MAIT cells may also be involved in the pathogenesis of multiple sclerosis (16).

In addition to their regulatory function, MAIT cells also possess proinflammatory functions like other innate-like lymphocytes. Le Bourhis et al (20) demonstrated that MAIT cells display antimicrobial capacity. Both human and mouse MAIT cells are activated by *Escherichia coli*-infected antigen-presenting cells in an MR1-dependent manner. MAIT cells show a protective role against *Mycobacterium abscessus* or *E coli* infections in mice. Human MAIT cells are capable of producing interferon- γ (IFN γ) and IL-17 and are found in *Mycobacterium tuberculosis*-infected lung tissues. Thus, MAIT cells play an antimicrobial function under these infectious conditions. Although accumulating evidence suggests that certain subsets of innate-like lymphocytes, such as NK cells, iNKT cells, and γ/δ T cells, are involved in the pathogenesis of arthritis in animal models of the disease, the role of MAIT cells in arthritis remains unknown (24–31).

We report herein that MAIT cells play a pathogenic role in murine models of arthritis. The disease severity of collagen-induced arthritis (CIA) in MAIT cell-deficient MR1^{-/-} DBA/1J mice was ameliorated compared with that of MR1^{+/+} DBA/1J mice. However, T cell responses to type II collagen (CII) and CII-specific serum antibody levels were comparable between CIA-induced MR1^{-/-} and MR1^{+/+} DBA/1J mice. We found that MR1^{-/-} C57BL/6J mice are much less suscep-

tible to collagen antibody-induced arthritis (CAIA) as compared to MR1^{+/+} C57BL/6J mice. MR1^{-/-} C57BL/6J mice reconstituted with adoptively transferred MAIT cells developed severe arthritis, suggesting that MAIT cells may be one of the effectors contributing to inflammation in arthritis. Finally, we investigated the cytokine-producing capacity of MAIT cells. No differences in IFN γ production by liver mononuclear cells (LMNCs) from MR1^{-/-} C57BL/6J and MR1^{+/+} C57BL/6J mice were observed upon TCR stimulation, but the level of IL-17 produced by LMNCs from MR1^{+/+} C57BL/6J mice was much higher than that produced by cells from MR1^{-/-} C57BL/6J mice. We further demonstrated that sorted murine MAIT cells produce IL-17 upon TCR engagement. Surprisingly, IL-17 production by MAIT cells was observed after exposure to IL-23 without TCR stimulation, and IL-1 β alone induced proliferation of MAIT cells, indicating that MAIT cells may be activated by cytokines and may enhance the inflammation in arthritis.

MATERIALS AND METHODS

Mice. DBA/1J mice were purchased from the Oriental Yeast Company. C57BL/6J mice were obtained from CLEA Laboratory Animal Corporation. MR1^{-/-} mice (14) were provided by S. Gilfillan (Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO), and $V_{\alpha}19i$ -transgenic mice (32) on a C57BL/6J background were provided by M. Shimamura (University of Tsukuba, Ibaraki, Japan). MR1^{-/-} mice were backcrossed to DBA/1J mice for 10 generations to obtain MR1^{-/-} DBA/1J mice. $V_{\alpha}19i$ -transgenic CD1d1^{-/-} C57BL/6J mice were generated by backcrossing $V_{\alpha}19i$ -transgenic mice with CD1d1^{-/-} C57BL/6J mice for 7 generations. Mice were maintained under specific pathogen-free conditions in accordance with institutional guidelines and used in the experiments at 7–12 weeks of age.

Induction of CIA. Both MR1^{-/-} DBA/1J mice and their littermate controls (MR1^{+/+} DBA/1J mice) (n = 5–6 per group; ages 7–8 weeks old) were immunized intradermally at the base of the tail with 150 μ g of CII (Collagen Research Center) emulsified with an equal volume of complete Freund's adjuvant containing 250 μ g of heat-killed *Mycobacterium tuberculosis* H37Ra (Difco). Three weeks after the primary immunization, mice were given an intradermal booster injection of 150 μ g of CII emulsified in incomplete Freund's adjuvant (Difco).

Induction of CAIA. MR1^{-/-} C57BL/6J mice and their littermate controls (MR1^{+/+} C57BL/6J mice) were injected intravenously with a mixture of anti-CII monoclonal antibodies (mAb) (Arthrogen-CIA mAb, 2 mg; Chondrex) followed 2 days later by an intraperitoneal injection of 50 μ g of lipopolysaccharide.

Clinical assessment of arthritis. Mice were examined for signs of joint inflammation, which was scored on a scale of 0–4, where 0 = no change, 1 = significant swelling and redness

of 1 digit, 2 = mild swelling and erythema of the limb or swelling of ≥ 2 digits, 3 = marked swelling and erythema of the limb, and 4 = maximal swelling and redness of the limb and later, ankylosis. The average macroscopic score was expressed as a cumulative value for all paws, with a maximum possible score of 16.

Histopathologic assessment. Arthritic mice were killed, and all 4 paws were fixed in buffered formalin, decalcified, embedded in paraffin, sectioned, and then stained with hematoxylin and eosin. Histologic assessment of joint inflammation was scored on a scale of 0–3 as follows: 0 = normal joint, 1 = mild arthritis (minimal synovitis without cartilage/bone erosion), 2 = moderate arthritis (synovitis and erosion but joint architecture maintained), and 3 = severe arthritis (synovitis, erosion, and loss of joint integrity). The average of the macroscopic scores was expressed as a cumulative value for all paws, with a maximum possible score of 12.

CII-specific T cell response. Lymph node cells were collected on days 35–42 after immunization and suspended in complete RPMI 1640 medium (Life Technologies) containing 1% syngeneic mouse serum. The cells were cultured for 72 hours in 96-well flat-bottomed plates at a density of 1×10^6 /well in the presence of CII. Proliferative responses were measured using a β -1205 counter (Pharmacia) to detect the incorporation of ^3H -thymidine ($1 \mu\text{Ci}/\text{well}$) during the final 16 hours of culture.

Measurement of CII-specific total IgG, IgG1, and IgG2a. Bovine CII (1 mg/ml) was coated onto enzyme-linked immunosorbent assay (ELISA) plates (Sumitomo Bakelite) overnight at 4°C . After blocking with 1% bovine serum albumin in PBS, serially diluted serum samples were added to CII-coated wells. For detection of anti-CII antibodies, the plates were incubated with biotin-labeled anti-IgG1 and anti-IgG2a (SouthernBiotech) or anti-IgG antibody (CN/Cappel) for 1 hour and were then incubated with streptavidin-peroxidase. After adding substrate, the reaction was evaluated as the optical density values at 450 nm (OD_{450}).

Adoptive transfer and in vitro stimulation of $V_\alpha 19i$ T cells. LMNCs were purified from $V_\alpha 19i$ -transgenic $\text{CD1d1}^{-/-}$ $\text{C57BL}/6\text{J}$ mice by use of Percoll density-gradient centrifugation, and erythrocytes and B cells were depleted with phycoerythrin (PE)-conjugated anti-Ter-119 and PE-conjugated anti-CD19 (BD) followed by separation with anti-PE-conjugated magnetic-activated cell sorter beads (Miltenyi Biotec). Cells were stained with fluorescein isothiocyanate-conjugated anti-TCR β and PerCP-Cy5.5 anti-NK1.1 (BD), and TCR β^+ NK1.1 $^+$ cells were sorted using a FACSAria cell sorter (BD). The purity of isolated NK1.1 $^+$ T cells (MAIT cells) was $>95\%$, as assessed by flow cytometry.

In adoptive transfer experiments, 5×10^5 MAIT cells or NK1.1 $^-$ T cells (T cells) were injected intravenously into naive $\text{MR1}^{-/-}$ $\text{C57BL}/6$ recipient mice 1 day before administration of CII mAb. LMNCs or sorted MAIT cells were resuspended in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 50 units/ml of penicillin/streptomycin, and 55 μM β -mercaptoethanol (Life Technologies) and stimulated with immobilized anti-CD3 mAb (2C11, 1 $\mu\text{g}/\text{ml}$) and/or the following cytokines: IL-1 β , tumor necrosis factor α (TNF α), IL-6, and transforming growth factor β (TGF β) (all from PeproTech) and IL-23 (R&D Systems).

Detection of cytokines. Cytokine levels in the culture supernatant were determined using a sandwich ELISA. The




Figure 1. Amelioration of collagen-induced arthritis (CIA) in $\text{MR1}^{-/-}$ mice. **A**, Clinical scores for CIA in $\text{MR1}^{-/-}$ DBA/1J mice and in $\text{MR1}^{+/+}$ DBA/1J mice. Values are the mean \pm SEM of 5–8 mice per group. * = $P < 0.05$ versus $\text{MR1}^{-/-}$ DBA/1J mice. **B**, Representative histologic sections of the joints of $\text{MR1}^{+/+}$ DBA/1J mice and $\text{MR1}^{-/-}$ DBA/1J mice. Hematoxylin and eosin stained; original magnification $\times 40$. **C**, Histology scores in $\text{MR1}^{-/-}$ DBA/1J mice and in $\text{MR1}^{+/+}$ DBA/1J mice, expressed as the sum of the scores in the 4 paws. Results from a single representative experiment of 2 similar experiments performed are shown. Values are the mean \pm SEM. * = $P < 0.05$.

ELISA antibodies for IFN γ were purchased from BD. Levels of IL-17 were determined using an IL-17 ELISA kit (R&D Systems).

Statistical analysis. Clinical or pathologic scores for CIA and CAIA in the various groups of mice are presented as




Figure 2. Type II collagen (CII) responses in MR1^{-/-} DBA/1J mice. **A** and **B**, Inguinal lymph node cells from MR1^{-/-} DBA/1J mice and MR1^{+/+} DBA/1J mice with collagen-induced arthritis were incubated for 48 hours in the presence of CII. Proliferative responses were determined by the uptake of ³H-thymidine (**A**), and the levels of interferon- γ (IFN γ) and interleukin-17 (IL-17) in culture supernatants were measured by enzyme-linked immunosorbent assay (**B**). **C**, CII-specific antibody levels in individual serum samples obtained at the end of the experiment were analyzed as described in Materials and Methods. Results from a single representative experiment of 2 similar experiments performed are shown. Values are the mean \pm SEM of 5–8 mice per group. OD = optical density

the mean \pm SEM clinical score for the group, and statistical differences were analyzed with a nonparametric Mann-Whitney U test. Data for cytokines and proliferation were analyzed with an unpaired *t*-test.

RESULTS

Amelioration of CIA in MR1^{-/-} mice. To investigate whether MAIT cells play a role in the pathogenesis of arthritis, we first evaluated the involvement of MAIT cells in CIA using MR1^{-/-} mice lacking MAIT cells. Because DBA/1J mice bearing the H-2q haplotype are the most susceptible strain for CIA, MR1^{-/-} C57BL/6J mice were backcrossed to DBA/1J mice for 10 generations to obtain MR1^{-/-} DBA/1J mice. Both MR1^{-/-} DBA/1J mice and littermate MR1^{+/+} DBA/1J mice were immunized with CII to induce CIA, and the clinical severity of arthritis was evaluated by visual scoring of each paw. As shown in Figure 1A, the clinical scores in MR1^{-/-} DBA/1J mice were reduced in comparison to those in MR1^{+/+} DBA/1J mice. Histologic examination of the joints of the 4 paws 44 days after CIA induction showed less cell infiltration, cartilage erosion, and bone

destruction in MR1^{-/-} DBA/1J mice than in the MR1^{+/+} DBA/1J mice (Figure 1B). Quantification of the histologic severity of arthritis revealed that MR1^{-/-} DBA/1J mice developed milder joint inflammation than MR1^{+/+} DBA/1J mice (Figure 1C). These results suggest that MAIT cells contribute to the exacerbation of the disease course of CIA.

CII responses in MR1^{-/-} DBA/1J mice. As the presence of MAIT cells augmented the severity of CIA, we next asked whether MAIT cells influence the CII-specific responses of T and B cells. Lymph node cells from CIA-induced animals were rechallenged with CII ex vivo. As shown in Figure 2A, the proliferative responses of lymph node cells upon stimulation with CII were similar in the two groups. Lymph node cells from both MR1^{-/-} DBA/1J mice and MR1^{+/+} DBA/1J mice produced comparable amounts of IL-17 and IFN γ in response to CII in a dose-dependent manner (Figure 2B). We also evaluated CII-specific immunoglobulin levels in serum obtained 35–42 days after arthritis induction. We observed a trend of reduced levels of CII-specific IgG1 in MR1^{-/-} DBA/1J mice compared to the




Figure 3. Amelioration of collagen antibody-induced arthritis (CAIA) in MR1^{-/-} mice. **A**, Clinical scores for CAIA in MR1^{-/-} C57BL/6J mice and MR1^{+/+} C57BL/6J mice. Values are the mean ± SEM of 4–6 mice per group. * = *P* < 0.05 versus MR1^{-/-} C57BL/6J mice. **B**, Representative histologic sections of the joints of MR1^{+/+} C57BL/6J mice and MR1^{-/-} C57BL/6J mice. Hematoxylin and eosin stained; original magnification × 40. **C**, Histology scores in MR1^{-/-} C57BL/6J mice and in MR1^{+/+} C57BL/6J mice, expressed as the sum of the scores in the 4 paws. Results from a single representative experiment of 2 similar experiments performed are shown. Values are the mean ± SEM. * = *P* < 0.05.

levels in MR1^{+/+} DBA/1J mice, but the difference did not reach statistical significance (Figure 2C). These results indicate that the presence of MAIT cells has little effect on CII-specific responses.

Amelioration of CAIA in MR1^{-/-} mice. The CIA model requires both adaptive and innate immune responses for disease development, and T cells and B cells responding to CII are the major players in the initiation of the disease. Although we observed significant differences in both the clinical and pathologic severity of arthritis when comparing MR1^{-/-} DBA/1J mice to MR1^{+/+} DBA/1J mice (Figure 1), the CII-specific responses of T and B cells appeared not to depend on the presence of MAIT cells (Figure 2). Thus, we hypothesized that MAIT cells may influence the effector phase of arthritis. To test this hypothesis, we induced CAIA in MR1^{-/-} and MR1^{+/+} C57BL/6J mice. By 7 days after injection of anti-CII mAb, MR1^{+/+} C57BL/6J mice had developed severe arthritis, as assessed by clinical scores (Figure 3A). In contrast, the clinical scores in the MR1^{-/-} C57BL/6J mice were lower compared to those in the MR1^{+/+} C57BL/6J mice. Histologic assessment 10 days after arthritis induction revealed severe arthritis with leukocyte infiltration, synovial hyperplasia, pannus formation, cartilage erosion, and bone destruction in MR1^{+/+} C57BL/6J mice, whereas these features were milder in MR1^{-/-} C57BL/6J mice (Figures 3B and C).

Augmentation of arthritis in MR1^{-/-} mice by adoptive transfer of MAIT cells. To demonstrate that MAIT cells actually enhance disease severity in the




Figure 4. Augmentation of arthritis by adoptive transfer of mucosal-associated invariant T (MAIT) cells in MR1^{-/-} mice. MR1^{-/-} C57BL/6J mice received 5×10^5 NK1.1+TCR β + T cells (MAIT cells) or an equal number of NK1.1–TCR β + cells (T cells) from V α 19-transgenic CD1d1^{-/-} mice. One day later, collagen antibody-induced arthritis was induced in wild-type (WT) C57BL/6J mice, MR1^{-/-} C57BL/6J mice, and MR1^{-/-} C57BL/6J mice reconstituted with T cells or MAIT cells. Results pooled from 2 similar experiments performed are shown. Values are the mean ± SEM of 8–10 mice per group. * = *P* < 0.05 versus MR1^{-/-} C57BL/6J mice.




Figure 5. Cytokine-mediated mucosal-associated invariant T (MAIT) cell activation. **A**, Liver mononuclear cells from MR1^{+/+} C57BL/6J mice and MR1^{-/-} C57BL/6J mice were stimulated for 48 hours with immobilized anti-CD3 (α CD3) monoclonal antibody (mAb). The levels of interferon- γ (IFN γ) and interleukin-17 (IL-17) in culture supernatants were measured by enzyme-linked immunosorbent assay (ELISA). * = $P < 0.05$. **B**, MAIT cells were stimulated for 48 hours with immobilized anti-CD3 mAb, with or without IL-1 β , tumor necrosis factor α (TNF α), IL-23, or IL-6 plus transforming growth factor β (TGF β), and the levels of IL-17 were measured by ELISA. * = $P < 0.05$ versus anti-CD3 mAb stimulation alone. **C**, MAIT cells were stimulated with immobilized anti-CD3 mAb or the indicated cytokines, and IL-17 levels were measured. * = $P < 0.05$ versus unstimulated control. **D** and **E**, Proliferative responses after 48 hours of exposure to the indicated cytokines were determined as the uptake of ³H-thymidine. Results from a single representative experiment of 2 similar experiments performed are shown. * = $P < 0.05$ versus unstimulated control. Values in A–E are the mean \pm SEM.

CAIA model, we performed adoptive transfer experiments. Most NK1.1+ TCR β T cells within liver lymphocytes from CD1d1^{+/+} mice are iNKT cells, and we and other investigators previously demonstrated that the NK1.1+ TCR β T cell population in V α 19i-transgenic CD1d1^{-/-} mice is highly enriched in V α 19i TCR+ cells (15,17). Thus, to obtain MAIT cells, we isolated NK1.1+ TCR β T cells from V α 19i-transgenic CD1d1^{-/-} mice. We adoptively transferred these MAIT cells into MR1^{-/-} C57BL/6J mice, and 1 day later, we injected these mice with anti-CII mAb to induce CAIA. MR1^{-/-} C57BL/6J mice reconstituted with MAIT cells developed severe arthritis at a level similar to that of wild-type (WT) C57BL/6J mice (Figure 4). However, the transfer of an equal number of T cells into MR1^{-/-} C57BL/6J mice had little effect on the clinical arthritis scores. Taken together, these results suggest that the presence of MAIT cells augmented arthritis mainly by enhancing the inflammation in arthritis.

Cytokine-mediated MAIT cell activation. To understand the mechanism by which MAIT cells exacer-

bate the disease course of arthritis, we first compared the cytokine-producing capacity of T cells from MR1^{-/-} and WT C57BL/6J mice. Upon anti-CD3 mAb stimulation, LMNCs from MR1^{-/-} and WT C57BL/6J mice produced comparable amounts of IFN γ . However, the level of IL-17 was lower in MR1^{-/-} C57BL/6J mice than in WT C57BL/6J mice (Figure 5A).

It was recently demonstrated that human MAIT cells express the Th17-associated transcription factor retinoic acid receptor-related orphan nuclear receptor (ROR) and produce high levels of IL-17 (33). We therefore sought to determine whether mouse MAIT cells produce IL-17, which is known to play a pathogenic role in arthritis. MAIT cells were sorted from LMNCs obtained from V α 19i-transgenic CD1d1^{-/-} mice and were stimulated ex vivo with anti-CD3 mAb. As previously shown (34), MAIT cells produced large amounts of IL-17. In addition, IL-17 production by anti-CD3 mAb-stimulated MAIT cells was augmented in the presence of IL-23 (Figure 5B).

Innate-like lymphocytes such as iNKT cells and

γ/δ T cells are known to be activated by cytokines directly, without TCR stimulation. A combination of IL-12 and IL-18 activates iNKT cells to produce IFN γ , and IL-1 together with IL-23 induces IL-17 production by γ/δ T cells (31,35,36). We therefore next asked whether MAIT cells are activated directly by cytokines. MAIT cells were incubated with various cytokines without TCR stimulation, and cytokine concentrations in the culture supernatants were evaluated. Surprisingly, MAIT cells produced high levels of IL-17 after exposure to IL-23 in the absence of TCR stimulation (Figure 5C).

Inflammatory cytokines such as IL-1 β , TNF α , and IL-6 play critical roles in arthritis models and in human RA. Therefore, we next tested whether MAIT cells could be activated by these cytokines. As shown in Figure 5D, IL-1 β induced robust proliferation of MAIT cells, although cytokine production was not observed after exposure to these cytokines, including IL-1 β (data not shown). In addition, IL-23 did not induce proliferation of MAIT cells (Figure 5E). Thus, in the absence of TCR stimuli, IL-1 β induced the proliferation of MAIT cells and IL-23 promoted the production of IL-17 by MAIT cells.

DISCUSSION

Previous studies by our group as well as others revealed that iNKT cells play pathogenic roles in CIA and CAIA by inducing a Th1 or Th17 shift of autoimmune T cells and by augmenting the inflammation in arthritis (25–27). In the present study, we demonstrated that MAIT cells contribute to the severity of CIA and CAIA mostly by augmenting joint inflammation during the effector phase of arthritis. MR1^{-/-} mice were originally generated on the 129P2 background. Although MR1^{-/-} mice were backcrossed onto C57BL/6 or DBA/1J, we are not able to exclude the possibility that some residual sequence from the 129P2 mice affects the arthritis susceptibility of MR1^{-/-} C57BL/6 and MR1^{-/-} DBA/1J mice. However, since the reconstitution of MAIT cells induced severe CAIA in MR1^{-/-} C57BL/6 mice, the phenotype observed in MR1^{-/-} mice seems to be dependent on the lack of MAIT cells.

It has been revealed that there are CD1d-restricted T cells that are different from iNKT cells and do not express an invariant TCR α chain (V α 14–J α 18 in mice and V α 24–J α 18 in humans). Such CD1d-restricted T cells are called type II NKT cells and possess different functions from iNKT cells. Recently, CD1d-restricted NKT cells, which recognize murine type II collagen peptide 707–721, were reported to suppress CIA (37). It is not known whether there are distinct subsets with

different functions among MAIT cells or whether there are other T cells that are restricted by the MR1 molecule. As adoptively transferred V α 19i T cells augmented CAIA in MR1^{-/-} mice, MAIT cells include the population that enhances the inflammation in arthritis.

It was recently shown that IL-17-producing γ/δ T cells were observed in the joints of mice with CIA and that blocking a certain subset of IL-17-producing γ/δ T cells suppressed CIA (29). However, γ/δ T cells have been shown to be dispensable for the development of CIA (38). In addition, anti-CII-specific antibody levels were comparable between γ/δ T cell-deficient and wild-type mice. These findings suggest that MAIT cells and γ/δ T cells share similar roles in arthritis and that both are involved mainly in the effector phase of arthritis. It is known that γ/δ T cells as well as iNKT cells are increased during CIA. Because MAIT cells share similar features with γ/δ T cells and iNKT cells, MAIT cells may also be increased during CIA.

We observed a significant decrease in IL-17 production by LMNCs upon stimulation with anti-CD3 mAb in MR1^{-/-} mice compared to WT control mice. As sorted MAIT cells produced high amounts of IL-17 after anti-CD3 mAb stimulation, the major source of IL-17 responsible for the difference between MR1^{-/-} and WT mice seems to be MAIT cells. Th17 cells and iNKT cells have been shown to produce IL-21, which enhanced IL-17 production or induced proliferation of IL-17-producing cells (39). It is not known whether MAIT cells produce IL-21, but MAIT cells might augment IL-17 production by other LMNCs, including γ/δ T cells, through such mechanisms. Further studies to determine whether MAIT cells regulate γ/δ T cells under both physiologic and pathologic conditions, including in the presence of arthritis, will be of interest.

The frequency of murine γ/δ T cells is 1–5% in blood lymphocytes and 25–60% in gut lymphocytes. Human γ/δ T cells also comprise up to 2–3% of peripheral T cells (9,10). Although the precise frequency of murine MAIT cells is not known, it has been speculated that MAIT cells may comprise up to 10% of double-negative T cells in the gut lamina propria and <2% of double-negative T cells in the mesenteric lymph nodes, indicating that the frequency of murine MAIT cells is much lower than that of mouse γ/δ T cells (15). It has been suggested that γ/δ T cells are the predominant source of IL-17 in the joints of CIA mice, but IL-17-producing γ/δ T cells could not be detected in RA synovial tissue (31). Recently, Martin et al (23) revealed that human MAIT cells can be identified as V α 7.2+ CD161^{high} T cells, which are abundant in blood. In addition, human MAIT cells produce IL-17 and express

tissue-homing chemokine receptors (23). An IL-17-producing CD161^{high} T cell population has been described in human arthritic joints (40). Thus, it is possible that MAIT cells rather than γ/δ T cells play a major role in the pathogenesis of human RA.

CD4+ Th17 cells require IL-6/STAT-3 activation for the expression of ROR γ t, which is a crucial transcription factor for IL-17 production (41). However, some innate-like lymphocyte subsets, such as iNKT cells, γ/δ T cells, and lymphoid tissue-inducer (LTi)-like cells, are known to constitutively express ROR γ t, IL-1 receptor type I, and IL-23R (42). In addition, these IL-17-producing innate-like lymphocytes, including LTi cells, γ/δ T cells, and iNKT cells, secrete IL-17 when stimulated by IL-23 with or without IL-1 β . In this study, we demonstrated cytokine-mediated activation of MAIT cells. MAIT cells produced IL-17 in response to IL-23. Moreover, IL-1 β induced proliferation of MAIT cells. Thus, it is possible that MAIT cells may contribute to the disease progression of arthritis through another mechanism in addition to IL-17 production. In adoptive transfer experiments, MAIT cells augmented the disease severity of CIA in MR1-deficient mice. Thus, this result also indicates that MAIT cell-mediated exacerbation of arthritis may be induced by cytokines, without a requirement for TCR stimulation.

In EAE, disease suppression by MAIT cells was accompanied by a reduction in the production of cytokines, including IFN γ and IL-17, by T cells and increased IL-10 production by B cells. Encephalitogenic T cells play a major role in EAE (43,44). EAE can be induced in naive mice by transferring myelin-reactive T cells. T cell-targeted therapies, including anti-very late activation antigen 4 treatment, have been shown to suppress EAE. Although CIA was reduced in MR1^{-/-} DBA/1J mice, we observed a significant decrease in CII-specific IgG1 antibody levels in these mice as compared with their WT controls in some experiments (data not shown), suggesting the inhibition of Th1 responses by MAIT cells. Therefore, it is still possible that MAIT cells suppress Th1 response during the early induction phase of CIA. MAIT cells may be functionally plastic, and thus exert different functions depending on the pathologic condition. Arthritis involves massive cytokine production due to various types of immune cell activation. Since MAIT cells can be activated by inflammatory cytokines, MAIT cells may contribute to augment the immune response once overt inflammation occurs.

In summary, we have shown that MAIT cells contribute to the progression of arthritis by enhancing the inflammation in CIA and CAIA models. In addition, we demonstrated that MAIT cells could be activated by

cytokine stimulation even without TCR stimulation. We and others previously reported that, although iNKT cells play pathogenic roles in arthritis models, modulation of iNKT cell function by ligands successfully suppressed arthritis (45–47). The proportion of human MAIT cells appears to be much higher than that of mouse MAIT cells. Therefore, MAIT cells may play an important pathogenic role in human arthritis and MAIT cell-targeted therapy may hold promise as a new therapeutic intervention for arthritis, including RA.

ACKNOWLEDGMENTS

The authors thank S. Gilfillan (Washington University School of Medicine, St. Louis, MO) for MR1^{-/-} mice and M. Shimamura (University of Tsukuba, Ibaraki, Japan) for V α 19-transgenic mice.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Miyake had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Chiba, Tajima, Miyazaki, Miyake.

Acquisition of data. Chiba, Tajima, Tomi, Miyazaki.

Analysis and interpretation of data. Chiba, Tajima, Tomi, Miyazaki, Yamamura, Miyake.

REFERENCES

- Chervonsky AV. Influence of microbial environment on autoimmunity [review]. *Nat Immunol* 2010;11:28–35.
- Vaahtovuori J, Munukka E, Korkeamäki M, Luukkainen R, Toivanen P. Fecal microbiota in early rheumatoid arthritis. *J Rheumatol* 2008;35:1500–5.
- Stone M, Fortin PR, Pacheco-Tena C, Inman RD. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. *J Rheumatol* 2003;30:2112–22.
- Nieuwenhuis EE, Visser MR, Kavelaars A, Cobelens PM, Fleer A, Harmsen W, et al. Oral antibiotics as a novel therapy for arthritis: evidence for a beneficial effect of intestinal *Escherichia coli*. *Arthritis Rheum* 2000;43:2583–9.
- Wu HJ, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. *Immunity* 2010;32:815–27.
- Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells [review]. *Nat Immunol* 2008;9:503–10.
- Kronenberg M, Kinjo Y. Innate-like recognition of microbes by invariant natural killer T cells [review]. *Curr Opin Immunol* 2009;21:391–6.
- Brigl M, Brenner MB. How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens [review]. *Semin Immunol* 2010;22:79–86.
- Carding SR, Egan PJ. γ/δ T cells: functional plasticity and heterogeneity [review]. *Nat Rev Immunol* 2002;2:336–45.
- Bonneville M, O'Brien RL, Born WK. γ/δ T cell effector functions: a blend of innate programming and acquired plasticity [review]. *Nat Rev Immunol* 2010;10:467–78.
- Allman D, Pillai S. Peripheral B cell subsets [review]. *Curr Opin Immunol* 2008;20:149–57.

12. Lopes-Carvalho T, Foote J, Kearney JF. Marginal zone B cells in lymphocyte activation and regulation [review]. *Curr Opin Immunol* 2005;17:244–50.
13. Le Bourhis L, Guerri L, Dusseaux M, Martin E, Soudais C, Lantz O. Mucosal-associated invariant T cells: unconventional development and function [review]. *Trends Immunol* 2011;32:212–8.
14. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F, et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. *Nature* 2003;422:164–9.
15. Kawachi I, Maldonado J, Strader C, Gilfillan S. MR1-restricted V α 19i mucosal-associated invariant T cells are innate T cells in the gut lamina propria that provide a rapid and diverse cytokine response. *J Immunol* 2006;176:1618–27.
16. Illes Z, Shimamura M, Newcombe J, Oka N, Yamamura T. Accumulation of V α 7.2-J α 33 invariant T cells in human autoimmune inflammatory lesions in the nervous system. *Int Immunol* 2004;16:223–30.
17. Croxford JL, Miyake S, Huang YY, Shimamura M, Yamamura T. Invariant V α 19i T cells regulate autoimmune inflammation. *Nat Immunol* 2006;7:987–94.
18. Peterfalvi A, Gomori E, Magyarlakti T, Pal J, Banati M, Javorhazy A, et al. Invariant V α 7.2-J α 33 TCR is expressed in human kidney and brain tumors indicating infiltration by mucosal-associated invariant T (MAIT) cells. *Int Immunol* 2008;20:1517–25.
19. Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J, et al. Human mucosal associated invariant T cells detect bacterially infected cells. *PLoS Biol* 2010;8:e1000407.
20. Le Bourhis L, Martin E, Peguillet I, Guihot A, Froux N, Core M, et al. Antimicrobial activity of mucosal-associated invariant T cells. *Nat Immunol* 2010;11:701–8.
21. Tilloy F, Treiner E, Park SH, Garcia C, Lemonnier F, de la Salle H, et al. An invariant T cell receptor α chain defines a novel TAP-independent major histocompatibility complex class IB-restricted α/β T cell subpopulation in mammals. *J Exp Med* 1999;189:1907–21.
22. Lantz O, Bendelac A. An invariant T cell receptor α chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4–CD8– T cells in mice and humans. *J Exp Med* 1994;180:1097–106.
23. Martin E, Treiner E, Duban L, Guerri L, Laude H, Toly C, et al. Stepwise development of MAIT cells in mouse and human. *PLoS Biol* 2009;7:e54.
24. Lo CK, Lam QL, Sun L, Wang S, Ko KH, Xu H, et al. Natural killer cell degeneration exacerbates experimental arthritis in mice via enhanced interleukin-17 production. *Arthritis Rheum* 2008;58:2700–11.
25. Chiba A, Kaieda S, Oki S, Yamamura T, Miyake S. The involvement of V α 14 natural killer T cells in the pathogenesis of arthritis in murine models. *Arthritis Rheum* 2005;52:1941–8.
26. Kim HY, Kim HJ, Min HS, Kim S, Park WS, Park SH, et al. NKT cells promote antibody-induced joint inflammation by suppressing transforming growth factor β 1 production. *J Exp Med* 2005;201:41–7.
27. Ohnishi Y, Tsutsumi A, Goto D, Itoh S, Matsumoto I, Taniguchi M, et al. TCR V α 14 natural killer T cells function as effector T cells in mice with collagen-induced arthritis. *Clin Exp Immunol* 2005;141:47–53.
28. Teige A, Bockermann R, Hasan M, Olofsson KE, Liu Y, Issazadeh-Navikas S. CD1d-dependent NKT cells play a protective role in acute and chronic arthritis models by ameliorating antigen-specific Th1 responses. *J Immunol* 2010;185:345–56.
29. Roark CL, French JD, Taylor MA, Bendele AM, Born WK, O'Brien RL. Exacerbation of collagen-induced arthritis by oligoclonal, IL-17-producing $\gamma\delta$ T cells. *J Immunol* 2007;179:5576–83.
30. Peterman GM, Spencer C, Sperling AI, Bluestone JA. Role of $\gamma\delta$ T cells in murine collagen-induced arthritis. *J Immunol* 1993;151:6546–58.
31. Ito Y, Usui T, Kobayashi S, Iguchi-Hashimoto M, Ito H, Yoshitomi H, et al. Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis. *Arthritis Rheum* 2009;60:2294–303.
32. Okamoto N, Kanie O, Huang YY, Fujii R, Watanabe H, Shimamura M. Synthetic α -mannosyl ceramide as a potent stimulant for an NKT cell repertoire bearing the invariant V α 19-J α 26 TCR α chain. *Chem Biol* 2005;12:677–83.
33. Dusseaux M, Martin E, Serriari N, Peguillet I, Premel V, Louis D, et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161^{hi} IL-17-secreting T cells. *Blood* 2011;117:1250–9.
34. Shimamura M, Huang YY, Kobayashi M, Goji H. Altered production of immunoregulatory cytokines by invariant V α 19 TCR-bearing cells dependent on the duration and intensity of TCR engagement. *Int Immunol* 2009;21:179–85.
35. Nagarajan NA, Kronenberg M. Invariant NKT cells amplify the innate immune response to lipopolysaccharide. *J Immunol* 2007;178:2706–13.
36. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from $\gamma\delta$ T cells, amplifying Th17 responses and autoimmunity. *Immunity* 2009;31:331–41.
37. Liu Y, Teige A, Mondoc E, Ibrahim S, Holmdahl R, Issazadeh-Navikas S. Endogenous collagen peptide activation of CD1d-restricted NKT cells ameliorates tissue-specific inflammation in mice. *J Clin Invest* 2011;121:249–64.
38. Corthay A, Johansson A, Vestberg M, Holmdahl R. Collagen-induced arthritis development requires $\alpha\beta$ T cells but not $\gamma\delta$ T cells: studies with T cell-deficient (TCR mutant) mice. *Int Immunol* 1999;11:1065–73.
39. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity [review]. *Annu Rev Immunol* 2008;26:57–79.
40. Billerbeck E, Kang YH, Walker L, Lockstone H, Grafmueller S, Fleming V, et al. Analysis of CD161 expression on human CD8+ T cells defines a distinct functional subset with tissue-homing properties. *Proc Natl Acad Sci U S A* 2010;107:3006–11.
41. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations [review]. *Annu Rev Immunol* 2010;445–89.
42. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system [review]. *Nat Rev Immunol* 2010;10:479–89.
43. Wekerle H. Lessons from multiple sclerosis: models, concepts, observations [review]. *Ann Rheum Dis* 2008;67 Suppl III:iii56–60.
44. Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis [review]. *Clin Exp Immunol* 2010;162:1–11.
45. Chiba A, Oki S, Miyamoto K, Hashimoto H, Yamamura T, Miyake S. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of α -galactosylceramide. *Arthritis Rheum* 2004;50:305–13.
46. Coppieters K, Van Beneden K, Jacques P, Dewint P, Vervloet A, Vander Cruyssen B, et al. A single early activation of invariant NK T cells confers long-term protection against collagen-induced arthritis in a ligand-specific manner. *J Immunol* 2007;179:2300–9.
47. Kaieda S, Tomi C, Oki S, Yamamura T, Miyake S. Activation of invariant natural killer T cells by synthetic glycolipid ligands suppresses autoantibody-induced arthritis. *Arthritis Rheum* 2007;56:1836–45.

Type II NKT Cells Stimulate Diet-Induced Obesity by Mediating Adipose Tissue Inflammation, Steatohepatitis and Insulin Resistance

Masashi Satoh^{1,2,3}, Yasuhiro Andoh^{2,3,9}, Christopher Stuart Clingan^{2,4}, Hisako Ogura², Satoshi Fujii⁵, Koji Eshima¹, Toshinori Nakayama⁶, Masaru Taniguchi⁷, Noriyuki Hirata^{2,8}, Naoki Ishimori³, Hiroyuki Tsutsui³, Kazunori Ono², Kazuya Iwabuchi^{1,2,*}

1 Department of Immunology, Kitasato University School of Medicine, Sagami, Japan, **2** Division of Immunobiology, Research Section of Pathophysiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan, **3** Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan, **4** Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America, **5** Department of Molecular and Cellular Pathobiology and Therapeutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan, **6** Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan, **7** RIKEN Research Center for Allergy and Immunology, Yokohama, Japan, **8** Division of Cancer Biology, Research Section of Pathophysiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan

Abstract

The progression of obesity is accompanied by a chronic inflammatory process that involves both innate and acquired immunity. Natural killer T (NKT) cells recognize lipid antigens and are also distributed in adipose tissue. To examine the involvement of NKT cells in the development of obesity, C57BL/6 mice (wild type; WT), and two NKT-cell-deficient strains, $J\alpha 18^{-/-}$ mice that lack the type I subset and $CD1d^{-/-}$ mice that lack both the type I and II subsets, were fed a high fat diet (HFD). $CD1d^{-/-}$ mice gained the least body weight with the least weight in perigonadal and brown adipose tissue as well as in the liver, compared to WT or $J\alpha 18^{-/-}$ mice fed an HFD. Histologically, $CD1d^{-/-}$ mice had significantly smaller adipocytes and developed significantly milder hepatosteatosis than WT or $J\alpha 18^{-/-}$ mice. The number of $NK1.1^{+}TCR\beta^{+}$ cells in adipose tissue increased when WT mice were fed an HFD and were mostly invariant $V\alpha 14J\alpha 18$ -negative. $CD11b^{+}$ macrophages (M ϕ) were another major subset of cells in adipose tissue infiltrates, and they were divided into $F4/80^{high}$ and $F4/80^{low}$ cells. The $F4/80^{low}$ -M ϕ subset in adipose tissue was increased in $CD1d^{-/-}$ mice, and this population likely played an anti-inflammatory role. Glucose intolerance and insulin resistance in $CD1d^{-/-}$ mice were not aggravated as in WT or $J\alpha 18^{-/-}$ mice fed an HFD, likely due to a lower grade of inflammation and adiposity. Collectively, our findings provide evidence that type II NKT cells initiate inflammation in the liver and adipose tissue and exacerbate the course of obesity that leads to insulin resistance.

Citation: Satoh M, Andoh Y, Clingan CS, Ogura H, Fujii S, et al. (2012) Type II NKT Cells Stimulate Diet-Induced Obesity by Mediating Adipose Tissue Inflammation, Steatohepatitis and Insulin Resistance. PLoS ONE 7(2): e30568. doi:10.1371/journal.pone.0030568

Editor: Simon Afford, University of Birmingham, United Kingdom

Received: August 9, 2011; **Accepted:** December 19, 2011; **Published:** February 22, 2012

Copyright: © 2012 Satoh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported in part by Grant-in-Aid for Scientific Research (#B: #20390106) by the Japan Society for the Promotion of Science (JSPS), Global COE Program, Establishment of International Collaboration Center for Zoonosis Control, by the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) of Japan, a Health and Labor Sciences Research Grant on Intractable Diseases (Neuroimmunological Diseases) from the Ministry of Health, Labor and Welfare of Japan, and a Grant by Heisei Ijuku Tomakomai East Hospital. MS is a recipient of a Parent's Association (Keyaki Kai) Grant of Kitasa to University School of Medicine. No additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: akimari@kitasato-u.ac.jp

© These authors contributed equally to this work.

Introduction

Obesity is thought to progress with caloric excess under a chronic inflammatory process characterized by infiltration of adipose tissue by M ϕ and by cells of the adaptive immune system, such as T cells [1–3]. The inflammation in adipose tissue induces alterations in metabolic and endocrine functions of adipocytes, which leads to insulin resistance and various pathological responses [4,5]. Recent studies by Nishimura et al revealed the active participation of $CD8^{+}$ T cells in chronic inflammation in adipose tissue [6]. Moreover, $CD4^{+}Foxp3^{+}$ T cells with unique specificity have been detected in adipose tissue and were suggested to regulate the development of obesity by suppressing inflammatory responses [7]. Furthermore, additional findings showed that

the transfer of $CD4^{+}$ T cells from WT but not from T-cell receptor transgenic mice ameliorated the metabolic dysregulation in $Rag-1^{-/-}$ mice fed a high fat diet (HFD), which led to the idea that $CD4^{+}$ T cells play a suppressive role in diet-induced obesity (DIO) [8]. These studies have indicated that T cells that infiltrate adipose tissue are not just inert bystanders but are active modifiers of inflammation and thus either aggravate or ameliorate obesity.

Natural killer T (NKT) cells are a unique subset of T-lineage cells that recognize various lipid antigens in the context of $CD1d$ molecules [9]. Among lipid ligands, α -galactosylceramide (α -GalCer) is the prototype ligand [10] that can stimulate NKT cells to promptly produce large amounts of various cytokines and chemokines and also demonstrate cytotoxic activity [11]. Endogenous ligands can also stimulate NKT cells to perform their innate

effector functions [12]. Moreover, NKT cells localize to the liver [13], where lipid metabolism is active, and in adipose tissue [14], another location for lipid metabolism with endocrine functions. These considerations led us to suggest that, NKT cells might play a role in a disease that involves abnormal lipid metabolism or lipid-related inflammation. Indeed, several research groups including our team have demonstrated that NKT cells accelerate atherogenesis in a mouse model of atherosclerosis [15–17]. Furthermore, we have examined the involvement of NKT cells in insulin resistance induced in mice fed an HFD and demonstrated that NKT cells play an important role in adipose-tissue inflammation and glucose intolerance in β_2 -microglobulin knockout ($\beta_2m^{-/-}$) mice with DIO [18]. However, both mainstream $CD8^+$ T cells and various innate lymphocytes other than NKT cells also are absent in $\beta_2m^{-/-}$ mice [19]. Thus, we attempted to examine the involvement of NKT cells in DIO and insulin resistance using NKT cell-deficient mice. To this end, we compared B6 (WT) and two strains of NKT cell-deficient mice, $CD1d^{-/-}$ and $J\alpha 18^{-/-}$ mice on a B6 genetic background. Unlike our previous study in $\beta_2m^{-/-}$ mice [18], DIO was significantly suppressed in $CD1d^{-/-}$ mice compared to WT mice. Moreover, in $J\alpha 18^{-/-}$ mice where type I but not type II NKT cells were deficient, DIO was induced to an equal extent as in WT mice. The possible mechanisms underlying lipid-induced NKT-cell activation and the development of chronic inflammation by type II NKT cells in DIO are discussed.

Materials and Methods

Mice

Male and female 8-week-old C57BL/6 (B6; Nippon SLC, Shizuoka, Japan), $B6.CD1d^{-/-}$ [20], and $B6.J\alpha 18^{-/-}$ [21] mice were used. Mice were maintained on food and water *ad libitum* until they reached the desired weight (20–24 g) or age (8 wk) under specific pathogen-free conditions. All experiments were approved by the Committees of Animal Experimentation at Hokkaido University (permit number: #09-0022) and Kitasato University (permit number: #2011 105).

Diet-induced obesity

Mice were fed either regular chow as a standard fat diet (SFD; Nihon Nosan: fat 4.3%, cholesterol 0.03%, protein 18.3%, carbohydrate 58.3%) or an HFD (CLEA Japan HFD-32: fat (powdered tallow and safflower oil of high oleic type) 32.0%, protein 25.5%, fiber 2.9%, mineral 4.0%, nitrogen 29.4%, water 6.2%) starting from 8 wk of age for 18 wk. Mice were weighed weekly. The ingredients of HFD-32 are listed in detail at <http://www.clea-japan.com/Feed/pdf/clea_hfd32.pdf>. Major fatty acids included oleic acid ($C_{18:1}$; 64.3%), palmitic acid ($C_{16:0}$; 12.6%), linoleic acid ($C_{18:2}$; 10.2%), and stearic acid ($C_{18:0}$; 7.5%). After 18 wk of feeding, mice were sacrificed for analysis. For some experiments, mice were injected intraperitoneally with α -GalCer (0.1 μ g/g body weight, BW) or vehicle as control to examine the change of BW.

Blood chemistry

Total cholesterol (T-cho), high-density lipoprotein (HDL) cholesterol (HDL-cho), triglyceride (TG), and alanine aminotransferase (ALT) concentrations in sera were quantified by colorimetric assays with the Fuji Drychem system (Fujifilm Medical, Osaka, Japan) according to the manufacturer's protocol, as described elsewhere [16].

Histology and quantitative analyses of microscopic images

Perigonadal fat tissue was removed and fixed with buffered formaldehyde solution (10%) followed by ordinary processing for

paraffin-embedded sections and hematoxylin-eosin (HE) staining. Images of the HE-stained adipose tissue were incorporated with a BIOREVO microscope (BZ8100; Keyence Corp., Osaka, Japan), and morphometric analyses were performed with image analysis software (BZ-H2A, -H1C) equipped on the microscope. Liver samples were snap-frozen in OCT compound (Sakura Finetek Co., Tokyo, Japan) with liquid nitrogen, and cryosections were stained with Oil Red O (ORO) (Sigma Chemical Co., St. Louis, MO) and Meyer's hematoxylin (Wako Pure Chemical Co. Ltd., Osaka, Japan). Images of lipid droplets in hepatocytes stained red were quantified by computerized image analysis system (Scion Image software, Scion Corp., Frederick, MD).

Flow cytometry

Splenocytes were prepared by mincing the spleen with a glass homogenizer, and red blood cells were lysed with Tris- NH_4Cl solution. Hepatic mononuclear cells (HMNC) were isolated from liver homogenates by density-gradient centrifugation with 33% PercollTM (GE Healthcare Life Sciences, Piscataway, NJ) as previously reported [22]. Stromal vascular cells were isolated from the digest of perigonadal fat by mincing and incubating with collagenase D solution (2 mg/ml) (Roche Diagnostics, Indianapolis, IN) for 1–1.5 h. The cells were incubated with 2.4G2 monoclonal antibody (mAb) (anti-Fc γ RIII/II) to block non-specific binding of primary mAb and then reacted with $CD1d$:Ig recombinant fusion protein (BD Biosciences Pharmingen, San Diego, CA) loaded with α -GalCer (α -GalCer- $CD1d$ -dimer), followed by detection with phycoerythrin (PE)-conjugated anti-mouse IgG₁ mAb (A85-1; BD) according to the manufacturer's protocol [16]. After washing, cells were stained with a combination of the following mAb conjugates: fluorescein isothiocyanate (FITC)-anti-TCR β chain (H57-597; BD), -anti- $CD3\epsilon$ (145-2C11; BD), -anti- $CD1d$ (1B1; BD), -anti- $CD206$ (MR5D3; BioLegend, San Diego, CA), -rat IgG_{2a} (BD), -rat IgG_{2b} (BD), allophycocyanin (APC)-anti-NK1.1 (PK136; BD, BioLegend), -anti- $CD11c$ (HL3; BD), -Streptavidin (BioLegend), PE-anti- $CD4$ (RM4-5; BD), -anti- $CD8$ (53-6.7; BD), -anti- $CD11b$ (M1/70; BioLegend), and APC-Cy7-Streptavidin (BD). Stained cells were acquired with FACS Calibur or Canto II flow cytometers (BD Bioscience Immunocytometry Systems, San Jose, CA) and analyzed with CellQuest, FACS Diva (BDIS), or FlowJo (Tommy Digital Biology, Tokyo, Japan) software as described elsewhere [16]. Propidium iodide (PI; Sigma) or 7-aminoactinomycin D (7-AAD; BD) positive cells were electronically gated as dead cells from the analysis.

Quantification of serum cytokines and adipokines

The concentration of Th1/Th2 and inflammatory cytokines, including IFN- γ , tumor necrosis factor (TNF)- α , IL-1 α , 2, 4, 5, 6, 10, 17, and GM-CSF in serum was quantified with Mouse Th1/Th2 10plex FlowCytomixTM Multiplex (Bender MedSystems GmbH, Vienna, Austria) according to the manufacturer's protocol with a flow cytometer. Leptin (Morinaga Institute of Biological Sciences, Kanagawa, Japan) in sera was respectively quantified with enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturers' protocol.

IPGTT and insulin tolerance test

Intraperitoneal (*i.p.*) glucose tolerance test (IPGTT) was performed by *i.p.* injection of glucose solution (1 g/kg) after 16 h of fasting [6]. The insulin tolerance test (ITT) was performed by *i.p.* injection of insulin (0.75 IU/kg; Humulin R 100 U/ml; Eli Lilly Japan KK, Kobe, Japan) after 3.5 h of fasting. The blood glucose level was serially quantified with a blood glucose monitor (MEDISAFE MINI; Terumo Corp., Tokyo, Japan). The insulin

level was also quantified with the mouse insulin ELISA kit (Morinaga) according to the manufacturer's protocol.

HMNC transfer

HMNC were obtained from either $J\alpha 18^{-/-}$ or $CD1d^{-/-}$ mice and were intravenously transferred to $CD1d^{-/-}$ recipient mice (1×10^6 /mouse) at 8 wk. These mice were fed an HFD for 14 weeks and tested for IPGTT and ITT as above.

Culture of M ϕ from the stromal vascular fraction (SVF) of adipose tissue

Cells (1×10^5 /well) obtained from perigonadal adipose tissue were cultured in RPMI medium (supplemented with 10% heat-inactivated fetal calf serum, 100 U/ml penicillin, 100 μ g/ml streptomycin, and 50 μ M β -mercaptoethanol) with 1 μ g/ml LPS for 20 h. After 20 h, supernatants were collected and frozen at -80°C , and cytokines were later quantified as described above.

Statistical analysis

Results were demonstrated as means \pm standard deviation (s.d.). Statistical analysis between two groups was performed by Student's *t*-test and among three groups was performed using ANOVA followed by Tukey-Kramer tests. Pearson's correlation coefficient test was used to examine the correlation. Values with $P < 0.05$ were considered statistically significant.

Results

Impact of the presence of NKT cells on the weight gain of mice fed an HFD

Female or male B6 (WT), $B6.J\alpha 18^{-/-}$ ($J\alpha 18^{-/-}$), and $B6.CD1d^{-/-}$ ($CD1d^{-/-}$) mice were fed either an SFD or an HFD from 8 wk to 22~26 wk of age (for 14~18 wk), and the BW of each group of mice was plotted over time. Three groups of female (Figure 1A) or male (Figure 1B) mice showed a similar and gradual increase of BW when fed an SFD. On the other hand, all groups of female and male mice gained substantially more BW on HFD than those on SFD. However, $CD1d^{-/-}$ mice showed significantly less gains than those of WT and $J\alpha 18^{-/-}$ mice (Figure 1A, B). Consistently, the least difference was observed in $CD1d^{-/-}$ mice when the net gain ([BW on HFD at *n* wk] - [BW on SFD at *n* wk]; $n \geq 8$ wk) was compared (Figure 1C, D). We also compared BW in WT mice that received either the prototypical type I NKT cell ligand α -GalCer or vehicle when fed either an SFD or an HFD. There was no significant difference in weight gain between mice that received α -GalCer or vehicle and fed either an SFD or an HFD (Figure S1A), suggesting that type I NKT cells might have a minimal role in the development of DIO even when the activating ligand is provided.

When the daily food intake per animal was compared in each group of mice by calculating Σ [(amounts given - amounts left)/total periods] throughout the feeding periods, $CD1d^{-/-}$ female




Figure 1. Body weight and weight gain of three strains of mice fed an SFD or an HFD. (A, B) Body weight (BW) of female (A) and male mice (B) fed a high-fat diet (HFD) or a standard-fat diet (SFD) at 8 wk and weighed weekly. ($n = 3-7$ in each group) (C, D) Representative data of three similar experiments are shown. Weight gain ($\Delta BW = BW_{n \text{ wk}} - BW_{8 \text{ wk}}$; $n \geq 9$) of female (C) and male (D) mice. Each point represents mean \pm standard deviation (s.d.). Statistical analysis was performed according to the Tukey-Kramer test. $**p < 0.01$ (WT and $J\alpha 18^{-/-}$ vs $CD1d^{-/-}$). doi:10.1371/journal.pone.0030568.g001

mice took in slightly smaller amounts of both SFD and HFD than the other two strains, WT and $J\alpha 18^{-/-}$ mice (Figure 2A). A similar tendency in food intake was observed in male mice (data not shown).

The BW of $CD1d^{-/-}$ mice was significantly lower than that of WT and $J\alpha 18^{-/-}$ mice after 18 wk of HFD feeding (Figure 2B) ($WT = J\alpha 18^{-/-} > CD1d^{-/-}$; $p < 0.01$ between WT and $CD1d^{-/-}$; $J\alpha 18^{-/-}$ and $CD1d^{-/-}$). The difference in BW in each group of mice was attributable to the sum of the differences in weights of organs and tissues. Thus, the liver, perigonadal fat tissue (white adipose tissue; WAT) and fat tissue between the scapulae (brown adipose tissue; BAT) of each group were obtained and compared. Consistent with the differences in BW, $CD1d^{-/-}$ mice had lower liver weight (Figure 2C) ($WT = J\alpha 18^{-/-} > CD1d^{-/-}$; $p < 0.01$ between WT and $CD1d^{-/-}$; $p < 0.05$ between $J\alpha 18^{-/-}$ and $CD1d^{-/-}$), lower WAT weight (Figure 2D) ($WT \geq J\alpha 18^{-/-} > CD1d^{-/-}$; $p < 0.01$ between WT and $CD1d^{-/-}$; $J\alpha 18^{-/-}$ and $CD1d^{-/-}$) and lower BAT weight (Figure 2E) ($WT \geq J\alpha 18^{-/-} > CD1d^{-/-}$; $p < 0.01$ between WT and $CD1d^{-/-}$), when compared to those of sex-matched WT or $J\alpha 18^{-/-}$ mice fed an HFD (closed bar). In SFD-fed mice, there were no significant differences in the weights of the whole BW, liver, WAT, and BAT among the three groups of mice (Figure 2B–E; open bar).

When serum lipids were quantified in the three groups of mice fed an HFD, WT and $J\alpha 18^{-/-}$ mice exhibited significantly higher levels of T-chol- and HDL-chol than $CD1d^{-/-}$ mice (Figure S2A, B). The cholesterol level was consistent with the extent of adiposity, whereas the TG level was not different among the three groups (Figure S2C).

HFD-induced hepatosteatosis and adipocyte hypertrophy are ameliorated in $CD1d^{-/-}$ mice

First, livers were histologically examined for major causes of weight gain among three strains of mice on HFD. WT and $J\alpha 18^{-/-}$ mice on HFD had marked hepatosteatosis, which was revealed by red deposits on ORO staining (Figure 3A). On the other hand, livers of $CD1d^{-/-}$ mice that appeared less fatty exhibited lighter deposits on ORO staining (Figure 3A). The ORO-positive regions in $CD1d^{-/-}$ livers were significantly smaller than those of WT and $J\alpha 18^{-/-}$ mice (Figure 3B). The severity of steatosis appeared consistent with the liver weight and dyslipidemic level in each strain (Figure 2A and B). Furthermore, the ALT level, a marker of liver damage, was significantly suppressed in $CD1d^{-/-}$ mice (Figure 3C). We also quantified pro-inflammatory cytokines that were secreted from HMNC in mice fed an HFD upon stimulation with LPS. Production of IL-6 and TNF- α in culture supernatants was increased in WT and $J\alpha 18^{-/-}$ mice, whereas it was suppressed in HMNC cultures of $CD1d^{-/-}$ mice (Figure 3D, E). Thus, lipid-induced inflammation may be suppressed in the absence of $CD1d$ and $CD1d$ -restricted NKT cells.

Next, we similarly analyzed adipose tissues that also contribute to the difference in BW in the three groups of mice. $CD1d^{-/-}$ mice had apparently smaller adipocytes in adipose tissue even on HFD, whereas enlarged adipocytes occupied the entire tissue in WT and $J\alpha 18^{-/-}$ mice (Figure 4A). Of note, boundaries of adipocytes formed almost straight lines due to the close packing of adipocytes in WT mice (Figure 4A left panel). To compare adipocyte size in WAT of each group of mice, the circumference of




Figure 2. Physiological parameters of three strains of female mice fed an SFD or an HFD. (A) Food intake of mice in each group (g/mouse/day). (B–E) The body, liver, perigonadal adipose tissue (WAT), and brown adipose tissue (BAT) were weighed after 18 wk of feeding at 26 wk of age ($n = 3-7$ in each group). Representative data of three similar experiments are shown. The results are expressed as mean \pm s.d. Statistical analysis was performed according to the Tukey-Kramer test. * $p < 0.05$, ** $p < 0.01$. doi:10.1371/journal.pone.0030568.g002